|
Apr 30
|
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
|
|
Mar 20
|
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
|
|
Mar 18
|
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
|
|
Mar 15
|
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
|
|
Mar 14
|
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
|
|
Mar 8
|
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
|
|
Mar 7
|
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
|
|
Mar 7
|
President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)
|
|
Mar 6
|
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
|
|
Mar 5
|
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
|
|
Mar 4
|
Akero Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Mar 4
|
Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
|
|
Mar 4
|
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
|
|
Mar 4
|
Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market
|
|
Mar 4
|
UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients
|
|
Mar 4
|
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
|
|
Mar 4
|
Akero strengthens MASH drug’s case with new study data
|
|
Jan 3
|
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 18
|
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
|
|
Dec 13
|
Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ...
|